One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.
Scientists have assembled the most complete human genome to be mapped with a single technology using a new pocket-size portable DNA sequencer, which they say could one day make genome mapping quick and simple enough to do at home.
Japan’s Takeda Pharmaceutical Co. Ltd. said on Monday the U.S. Food and Drug Administration granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus.
The EU’s CHMP adopted a positive opinion for Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with hemophilia A with factor VIII inhibitors.
A federal jury found AbbVie not liable in a lawsuit by an Arizona man who claimed he suffered a pulmonary embolism due to using the company’s testosterone replacement medication AndroGel.
The U.S. Securities and Exchange Commission filed an insider trading lawsuit against “unknown traders” who it said engaged in “highly suspicious trading” just ahead of the announcement that hemophilia specialist Bioverativ Inc. agreed to be acquired by France’s Sanofi in an $11.6 billion deal.
Outcome Health, a Chicago-based company that provides health education technology to improve patient outcomes at physician practices nationwide, announced that it has settled all litigation with its investors.
Following a disappointing 2017 that included an agreement to pay $40 million to resolve criminal charges against its subsidiary Aegerion, Canada-based Novelion Therapeutics will slash an unknown number of jobs as it initiates “significant cost reduction plans.”
The U.S. Food and Drug Administration approved French drugmaker Advanced Accelerator Application SA’s drug to treat patients with a type of digestive tract cancer.
Industry insiders say Johnson & Johnson is no longer interested in Pfizer’s $20 billion consumer healthcare business
A European Medicines Agency (EMA) panel recommended granting marketing approval to the diabetes drug Steglatro developed by Merck & Co. Inc. and Pfizer Inc.
AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late-stage trial that could challenge GlaxoSmithKline’s new three-in-one inhaler.
Gene testing company Illumina won a jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a Roche subsidiary, of using patented prenatal testing technology without authorization.
Seniors who get a flu shot every year are less likely to be hospitalized with severe influenza infections or to die from them than those who get vaccinated only sporadically, a study suggests.
Biogen acquired an IND-ready asset from Karyopharm Therapeutics for $10 million upfront.
Two former executives of Sanofi and Merrimack Pharmaceuticals launched Partner Therapeutics (PTx) to focus on oncology.
Takeda Pharmaceutical and development partner Zinfandel Pharmaceuticals pulled the plug on their five-year Phase III TOMMORROW trial following an interim analysis.
Amneal Pharmaceuticals is planning an expansion of its New York facilities that will create hundreds of jobs as the company and Impax Laboratories near completion of a planned merger.
ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’.
Synergy Pharmaceuticals Inc. announced that the U.S. FDA approved Trulance (plecanatide) 3-mg tablet for the once-daily treatment of irritable bowel syndrome with constipation in adults.